189 related articles for article (PubMed ID: 24119613)
1. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
[TBL] [Abstract][Full Text] [Related]
2. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
[TBL] [Abstract][Full Text] [Related]
4. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
Meijer P; Verbruggen B
Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
[TBL] [Abstract][Full Text] [Related]
5. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
Duncan E; Collecutt M; Street A
Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
[TBL] [Abstract][Full Text] [Related]
6. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
Verbruggen B; van Heerde WL; Laros-van Gorkom BA
Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
[TBL] [Abstract][Full Text] [Related]
7. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
Millner AH; Tiefenbacher S; Robinson M; Boesen HT
Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
[TBL] [Abstract][Full Text] [Related]
8. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
Favaloro EJ; Bonar R; Kershaw G; Mohammed S; Duncan E; Marsden K;
Haemophilia; 2010 Jul; 16(4):662-70. PubMed ID: 20070382
[TBL] [Abstract][Full Text] [Related]
9. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
Feng HM; Li Q; Xu WS; Chen DM; Zheng L
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
[TBL] [Abstract][Full Text] [Related]
10. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.
Favaloro EJ; Bonar R; Kershaw G; Duncan E; Sioufi J; Marsden K
Semin Thromb Hemost; 2009 Nov; 35(8):794-805. PubMed ID: 20169516
[TBL] [Abstract][Full Text] [Related]
11. External quality assessment of factor VIII inhibitor assays.
Bonar RA; Favaloro EJ; Marsden K
Semin Thromb Hemost; 2013 Apr; 39(3):320-6. PubMed ID: 23436565
[TBL] [Abstract][Full Text] [Related]
12. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
Kim SY; Kang SY; Lee WI
Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
[TBL] [Abstract][Full Text] [Related]
13. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
Batty P; Riddell A; Kitchen S; Sardo Infirri S; Walker I; Woods T; Jennings I; Hart DP
Haemophilia; 2021 May; 27(3):490-499. PubMed ID: 33650732
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.
Gandhi T; Lawler P; Foxton E; Chowdary P; Riddell A
Haemophilia; 2020 Nov; 26(6):e300-e307. PubMed ID: 32892451
[TBL] [Abstract][Full Text] [Related]
16. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
Valke LLFG; Verhagen MJA; Mulders BTPM; Polenewen R; Blijlevens NMA; Jansen JH; Mansouritorghabeh H; Elsheikh E; Reipert BM; Turecek PL; O'Donnell JS; Rijpma SR; Schols SEM; van Heerde WL; Meijer D
Thromb Res; 2023 Nov; 231():112-120. PubMed ID: 37844518
[TBL] [Abstract][Full Text] [Related]
17. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
Torita S; Suehisa E; Kawasaki T; Toku M; Takeo E; Tomiyama Y; Nishida S; Hidaka Y
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):185-9. PubMed ID: 21245748
[TBL] [Abstract][Full Text] [Related]
18. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
19. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
Kershaw G; Jayakodi D; Dunkley S
Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
